PATIENT INFORMATION

VEKLURY® (VEK-lur-ee)
(remdesivir)
for injection

VEKLURY® (VEK-lur-ee)
(remdesivir)
injection

What is VEKLURY?

VEKLURY is a prescription medicine used for the treatment of coronavirus disease 2019 (COVID-19) in adults and children weighing at least 3 pounds (1.5 kg) who are:

- Hospitalized, **or**
- Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

It is not known if VEKLURY is safe and effective in children weighing less than 3 pounds (1.5 kg).

Do not take VEKLURY if you are allergic to remdesivir or any of the ingredients in VEKLURY. See the end of this leaflet for a complete list of ingredients in VEKLURY.

Before receiving VEKLURY, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- are pregnant or plan to become pregnant. It is not known if VEKLURY may harm your unborn baby if taken during the first trimester of pregnancy. **Tell your healthcare provider right away if you are or if you become pregnant.**
- are breastfeeding or plan to breastfeed. VEKLURY can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEKLURY may interact with other medicines.

Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate.

How will I receive VEKLURY?

- **Hospitalized**: VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for up to 10 days. Your healthcare provider will decide how many doses you need.
- **Not hospitalized:** VEKLURY is given to you through a vein by intravenous (IV) infusion one time each day for 3 days.
- Your healthcare provider will do certain blood tests before starting and during treatment with VEKLURY.

What are the possible side effects of VEKLURY?

VEKLURY may cause serious side effects, including:

- **Allergic reactions.** Allergic reactions can happen during or after infusion with VEKLURY. Your healthcare provider will monitor you for signs and symptoms of allergic reactions during your infusion and for at least 1 hour after your infusion. Tell your healthcare provider right away if you get any of the following signs and symptoms of an allergic reaction:
  - changes in your heart rate
  - fever
  - shortness of breath, wheezing
  - swelling of the lips, face, or throat
  - rash
  - nausea
  - sweating
  - shivering
- **Increase in liver enzymes.** Increases in liver enzymes are common in people who have received VEKLURY and may be a sign of liver injury. Your healthcare provider will do blood tests to check your liver enzymes before and during treatment with VEKLURY as needed. Your healthcare provider may stop treatment with VEKLURY if you develop liver problems.

The most common side effect of VEKLURY is nausea.

These are not all of the possible side effects of VEKLURY.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of VEKLURY.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about VEKLURY that is written for healthcare professionals.

What are the ingredients in VEKLURY?
Active ingredient: remdesivir
Inactive ingredients:

VEKLURY for injection: betadex sulfobutyl ether sodium and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.

VEKLURY injection: betadex sulfobutyl ether sodium, Water for Injection, USP, and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.

Manufactured and distributed by: Gilead Sciences, Inc., Foster City, CA 94404

214787-GS-019
For more information, call 1-800-445-3235 or go to www.VEKLURY.com.

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 12/2024